Spots Global Cancer Trial Database for Clinical Benefit of Topoisomerase Downregulation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Benefit of Topoisomerase Downregulation
Official Title: Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study
Study ID: NCT00250094
Conditions
Interventions
Study Description
Brief Summary: 1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16) 1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
Detailed Description: The rationale to study the downregulation of topoisomerase enzyme in ovarian cancer in relationship to the cell cycle distribution of the cancer cells after a prolonged continuous exposure to topo I and II poisons is to better understand the relationship between cell cycle and topo poisoning, which may lead to better clinical trial designs.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of New Mexico, Albuquerque, New Mexico, United States
Contact Details
Name: Claire F Verschraegen, MD
Affiliation: University of New Mexico
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
